Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The 18th International Workshop on Multiple Myeloma (iwMyeloma) took place in Miami, FL, on April 10-13, 2025. This workshop brought together the world’s leading researchers to share their perspectives on how to place the evolving understanding of myeloma in a clinical context and thereby optimize clinical care. The iwMyeloma 2025 workshop was supported by Johnson & Johnson, Bristol Myers Squibb, Pfizer, Sanofi, Legend Biotech, Caribou Sciences, GSK, Regeneron, and AbbVie. Supporters have no influence over the production of content.
iwMyeloma 2025
The 18th International Workshop on Multiple Myeloma
10–13 April 2025 | Miami, FL
The 18th International Workshop on Multiple Myeloma (iwMyeloma) took place in Miami, FL, on April 10-13, 2025. This workshop brought together the world’s leading researchers to share their perspectives on how to place the evolving understanding of myeloma in a clinical context and thereby optimize clinical care. The iwMyeloma 2025 workshop was supported by Johnson & Johnson, Bristol Myers Squibb, Pfizer, Sanofi, Legend Biotech, Caribou Sciences, GSK, Regeneron, and AbbVie. Supporters have no influence over the production of content.
View all videos
Explore roundtable discussions
View all videos
Genomics and epigenomics
The genetic basis for racial disparity in MM
Kylee Maclachlan Memorial Sloan Kettering Cancer Center, New York, NY, United States
Coming soon
Structural variation in MM in depth analysis of PDX model
Brian Walker Sylvester Comprehensive Cancer Center, Miami, FL, United States
Coming soon
Resistance mechanisms
Tumor intrinsic resistance mechanisms to immunotherapy
Michael Durante Sylvester Comprehensive Cancer Center, Miami, FL, United States
Coming soon
Focal and breakout lesions in the evolution of resistance
Niels Wienhold Heidelberg University, Heidelberg, Germany
Biallelic antigen escape as a mechanism of resistance to anti-CD38 antibodies
Benjamin Diamond Sylvester Comprehensive Cancer Center, Miami, FL, United States
Biological models and single cell analyses
Modeling MM genetic and immune heterogeneity in mice
José Ángel Martínez-Climent University of Navarra, Pamplona, Spain
Complex human bone marrow organoids for the study of MM
Sarah Gooding Radcliffe Department of Medicine, Oxford, United Kingdom
Coming soon
Epigenetic and metabolic drivers of progression
Felipe Prósper University of Navarra, Navarra, Spain
Genomic profiling of precursor disease
Bachisio Ziccheddu Sylvester Comprehensive Cancer Center, Miami, FL, United States
Update on MRD as a clinical endpoint
ODAC meeting content – what does it mean going forward?
Ola Landgren Sylvester Comprehensive Cancer Center, Miami, FL, United States
Coming soon
Review of the ODAC regulatory perspectives on MRD in myeloma
Dickran Kazandjian Sylvester Comprehensive Cancer Center, Miami, FL, United States
Clinical trial updates
Emerging approaches for use of bispecific antibodies in precursors
Ola Landgren Sylvester Comprehensive Cancer Center, Miami, FL, United States
Coming soon
The emerging role of belantamab mafodotin
Rafael Fonseca Mayo Clinic, Phoenix, AZ, United States
Efficacy and safety of isatuximab combinations in frontline & relapsed myeloma
Thomas Martin University of California, San Francisco, CA, United States
Coming soon
Daratumumab combinations their current and future role
Dickran Kazandjian Sylvester Comprehensive Cancer Center, Miami, FL, United States
Clinical & translational research with MMRF
The HORIZON adaptive trial platform
Nitya Nathwani City of Hope, Duarte, CA, United States
Translational studies of the MyDrug trial MEKi arm
Chaitanya Acharya Multiple Myeloma Research Foundation, Durham, NC, United States
Tumor and microenvironment insights from Immune Atlas
Reyka Jayasinghe Washington University, School of Medicine , St. Louis, MO, United States
Novel targets
Keynote lecture: The spatio-temporal evolution of multiple myeloma
Leo Rasche Würzburg University Hospital, Würzburg, Germany
The role of allogeneic BCMA-targeting CAR-T cells in RRMM
Sham Mailankody Memorial Sloan Kettering Cancer Centre, New York City, NY, United States
Single-cell RNA analysis of the bone marrow stromal compartment in myeloma
Faith Davies NYU Langone Health, New York City, NY, United States
CAR-T cells targeting novel membrane-based antigens
Arun Wiita University of California San Francisco, San Francisco, CA, United States
Novel biomarkers for guiding the use of immunotherapies
Frank Zhan University of Arkansas for Medical Sciences, Little Rock, AR, United States
Coming soon
Part 1: Bispecifics
The current and future use of teclistamab
Saad Usmani Memorial Sloan Kettering Cancer Center, New York, NY, United States
Coming soon
The current use and development of talquetamab
Ciara Freeman Moffitt Cancer Center, Tampa, FL, United States
Update on the clinical data using elranatamab
Gareth Morgan NYU Langone Health, New York City, NY, United States
Latest progress with linvoseltamab
Louis Williams Cleveland Clinic, Cleveland, OH, United States
Progress with the novel optimized bispecific ABBV-383
Rachid Baz Moffitt Cancer Center, Tampa, FL, United States
Part 2: CAR-T
The development and application of ADC for use in MM
Hans Lee The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Coming soon
The development and potential of Anito-cel
Matthew Frigault Massachusetts General Hospital, Boston, MA, United States
Update on the use of allogeneic anti-BCMA CAR-T CB-011
Adriana Rossi Mount Sinai School of Medicine, New York City, NY, United States
Exploiting innovative CAR-T designs and targets
Yi Lin Mayo Clinic, Rochester, MN, United States
The iwMyeloma 2025 workshop was supported by Johnson & Johnson, Bristol Myers Squibb, Pfizer, Sanofi, Legend Biotech, Caribou Sciences, GSK, Regeneron, and AbbVie. Supporters have no influence over the production of content.
